SCHEMBL4209446

SCHEMBL4209446

CCCCCCC(C)C(=O)NCc1cccc(-c2ccc(C=C(OCC)C(=O)O)cc2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERAP2 Q6P179 1/20 0.42
ERAP1 Q9NZ08 1/20 0.42
LNPEP Q9UIQ6 1/20 0.42
PTPN11 Q06124 1/20 0.38
PTGS2 P35354 2/20 0.38
EPHX2 P34913 3/20 0.37
AOC3 Q16853 2/20 0.36
HPGD P15428 1/20 0.36
TLR2 O60603 2/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
FNTA P49354 1/20 0.36
FNTB P49356 1/20 0.36
FAAH O00519 1/20 0.36
KDM4E B2RXH2 1/20 0.35
CYP3A4 P08684 1/20 0.35
GAA P10253 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4227732 0.93 ERAP2 (0.40) ERAP2ERAP1LNPEPPTPN11PTGS2
SCHEMBL5567588 0.79 PPARG (0.46) ERAP2ERAP1LNPEPKDM4ECYP3A4
SCHEMBL5359079 0.78 ERAP2 (0.42) ERAP2ERAP1LNPEPPTPN11EPHX2
SCHEMBL5359229 0.78 CDC25B (0.44) ERAP2ERAP1LNPEPHPGDLMNA
SCHEMBL4209444 0.77 AOC3 (0.47) AOC3
SCHEMBL4209450 0.77 AOC3 (0.47) AOC3
SCHEMBL4209438 0.77 AOC3 (0.47) AOC3
SCHEMBL5367299 0.76 PTPN11 (0.46) ERAP2ERAP1LNPEPPTPN11PTGS2
SCHEMBL5374062 0.76 ERAP2 (0.42) ERAP2ERAP1LNPEPPTPN11LMNA
SCHEMBL6184324 0.76 MMP2 (0.48) ERAP2ERAP1LNPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383652-B2 Biaromatic compounds that modulate PPAR-receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-26 US claimed
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-08 US claimed
US-8383652-B2 Biaromatic compounds that modulate PPAR-receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-26 US disclosed
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-08 US disclosed
EP-1943213-A2 PPAR MODULATING BIAROMATIC COMPOUNDS Galderma Research & Development (FR) 2008-07-16 EP disclosed
WO-2007049158-A2 PPAR MODULATING BIAROMATIC COMPOUNDS GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS PPARG, PPARD, PPARA ERAP2 2159/4885ERAP1 2548/4885LNPEP 3965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.